TAK-783 / Takeda - LARVOL DELTA

Expert discusses novel agents in development targeting EGFR, HER2+ NSCLC (OncLive) - "Janne: One of the challenges is that for our existing EGFR-targeted therapies, patients develop resistance, especially to drugs like osimertinib. There continues to be a need to develop new and novel therapies to overcome resistance....I think the goal will be to develop specific therapeutic approaches against specific resistance mechanisms, as opposed to using chemotherapy more broadly."

Interview